New biologic injection aims to ease stuffy nose and sinus pain in nasal polyp patients

NCT ID NCT06706817

Ongoing Symptom relief Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This study tests a biologic drug called tezepelumab (Tezspire) in 181 adults with chronic sinusitis and nasal polyps who are eligible for surgery. Participants receive injections every 4 weeks for 24 weeks. The goal is to see if the drug reduces nasal congestion and other sinus symptoms, potentially offering a non-surgical treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tezepelumab (Tezspire), a biologic injection
What this could lead to: If it works, this could offer a new option to relieve stuffy nose and sinus symptoms without surgery for people with nasal polyps.
What could go wrong: This is a single-arm study with no placebo group, so results may be less reliable. It is also a short 24-week treatment period, so long-term benefits or risks are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Rhinosinusitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Contacts and locations

Locations

Research Site

Newport Beach, California, 92663, United States
Research Site

Chicago, Illinois, 60611, United States
Research Site

Chestnut Hill, Massachusetts, 02467, United States
Research Site

Columbia, Missouri, 65201, United States
Research Site

Plovdiv, 4003, Bulgaria
Research Site

Sofia, 1431, Bulgaria
Research Site

Sofia, 1606, Bulgaria
Research Site

Hamilton, Ontario, L8S 1G5, Canada
Research Site

Québec, Quebec, G1L 3L5, Canada
Research Site

Québec, Quebec, G1V 4W2, Canada
Research Site

Le Kremlin-Bicêtre, 94270, France
Research Site

Marseille, 13005, France
Research Site

Nantes, 44093, France
Research Site

Pierre-Bénite, 69495, France
Research Site

Poitiers, 86000, France
Research Site

Toulouse, 31400, France
Research Site

Marburg, 35043, Germany
Research Site

Tübingen, 72076, Germany
Research Site

Villingen-Schwenningen, 78052, Germany
Research Site

Wiesbaden, 65183, Germany
Research Site

Budapest, 1085, Hungary
Research Site

Budapest, 1134, Hungary
Research Site

Nyíregyháza, 4400, Hungary
Research Site

Pécs, 7621, Hungary
Research Site

Bologna, 40139, Italy
Research Site

Catania, 95123, Italy
Research Site

Florence, 50139, Italy
Research Site

Padua, 35128, Italy
Research Site

Pisa, 56126, Italy
Research Site

Roma, 00168, Italy
Research Site

Rozzano, 20089, Italy
Research Site

Bialystok, 15-879, Poland
Research Site

Bydgoszcz, 85-231, Poland
Research Site

Lodz, 90-302, Poland
Research Site

Zawadzkie, 47-120, Poland
Research Site

Barcelona, 08003, Spain
Research Site

Barcelona, 08035, Spain
Research Site

Cadiz, 11011, Spain
Research Site

Madrid, 28041, Spain
Research Site

Salamanca, 37007, Spain
Research Site

Santiago de Compostela, 15706, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.